To examine metabolic factors that influence ketone production after sodium-glucose cotransport inhibitor (SGLT2) administration.
| INTRODUCTION
Sodium-glucose co-transport (SGLT2) inhibitors are a novel class of antidiabetic drugs that are approved by the US Food and Drug Administration for the treatment of Type 2 diabetes mellitus (T2DM). 1 Members of this class of drugs lower plasma glucose concentration by inhibiting renal glucose transport and by producing glucosuria. 1, 2 Because of their unique mechanism of action, SGLT2
inhibitors are effective in lowering plasma glucose concentration as monotherapy and in combination with all other antidiabetic agents including insulin. 2 Recent reports have demonstrated that some subjects receiving SGLT2 inhibitors experience clinically significant ketoacidosis events despite being normoglycaemic. [3] [4] [5] These euglycaemic ketoacidotic events following SGLT2 administration were reported primarily in patients with type 1 diabetes, 3, 4 and in those with type 2 diabetes as well. 5 In addition to lowering plasma glucose concentration, SGLT2
inhibitors exert multiple other metabolic actions in T2DM individuals. 6 They improve insulin sensitivity 7 and beta cell function, 8 stimulate an increase in basal rate of hepatic glucose production, lower fasting plasma insulin (FPI) concentration, stimulate glucagon secretion 7, 9 and switch fuel consumption from glucose to fat oxidation.
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Some of these metabolic actions of SGLT2 inhibitors can affect ketone production in T2DM patients. Recently, we 10 and others 11 demonstrated that administration of SGLT2 inhibitors in T2DM patients for 2 to 4 weeks caused significant increase in fasting plasma ketone concentration. To examine factors that regulate glucose and fat oxidation and could lead to increase in plasma ketone concentration in T2DM patients, we compared the effect of empagliflozin treatment on plasma glucose, insulin, glucagon, free fatty acid (FFA) and ketone concentration in T2DM and non-diabetic individuals before and day 1 and day 14 after treatment with empagliflozin.
| RESEARCH DESIGN AND METHODS

| Subjects
A total of 31 subjects, who were part of a study designed to examine 
| Analytical methods
| Calculations and statistical analysis
The Ketogenic Index was used to generate an index that predicts the risk of increase in plasma ketone concentration after empagliflozin administration. We examined the correlation, in the entire cohort, between plasma ketone concentration and plasma glucose concentration before and at day 1 after empagliflozin treatment, as well as with plasma insulin, glucagon and FFA concentration at day 1 after empagliflozin treatment. FPI and decrease in plasma glucose concentration significantly and inversely correlated with plasma ketone concentration, while plasma FFA concentration significantly correlated with plasma ketone concentration. Thus, we defined the Ketogenic Index as follows.
•
• FFA = plasma free fatty acid concentration (in mM) after starting treatment.
• FPI = fasting plasma insulin concentration (μU/mL) after starting treatment.
• FPG pre = fasting plasma glucose concentration (mg/dL) before starting treatment with empagliflozin.
• FPG treat = fasting plasma glucose concentration at day 1 after starting treatment with empagliflozin.
Addition of plasma glucagon concentration to the index did not significantly improve its correlation with plasma ketone concentration.
Values are presented as mean AE S.E.M. The difference between means was compared with ANOVA. Correlation between variables was tested with Pearson's correlation. Significance was set at P < .05.
| RESULTS
Treatment with empagliflozin resulted in glucosuria of 45 AE 4, 50 AE 5 and 97 AE 11 g/d in NGT, IFG and T2DM subjects, respectively. As anticipated, empagliflozin caused a 26 mg/dL and a 38 mg/ dL reduction in FPG concentration at day 1 and day 14, respectively (both P < .0001) in T2DM patients. Conversely, the FPG concentration in NGT subjects was not affected by empagliflozin treatment (95 mg/dL vs 96 mg/dL and 94 mg/dL before and at day 1 and 14 after treatment, respectively) despite a loss in urinary glucose of 45 g/d. Although urinary glucose loss was comparable in IFG and NGT subjects, empagliflozin caused a modest but significant reduction in FPG concentration (from 110 AE 2 to 104 AE 3 mg/dL, P < .01) in IFG subjects. Further, the magnitude of decrease in FPG concentration strongly and inversely correlated with FPG concentration (r = −0.80, P < .0001) ( Figure 1 ) and this relationship was maintained in non-diabetic subjects (r = −0.61, P < .01). Table 1 presents clinical characteristics of study participants.
As anticipated and as consistent with previous studies, 6-9 empagliflozin caused a significant decrease (by 27%, P = .05) in FPI concentration and a large increase in fasting plasma glucagon concentration at day 1 in T2DM patients ( Table 2 ). The increase in fasting plasma glucagon was maintained at day 14; however, FPI concentration returned to pretreatment level at day 14. Conversely, empagliflozin did not significantly affect the FPI and fasting plasma glucagon concentrations in NGT and IFG subjects. 
| Relationship between plasma ketone, insulin, glucose and FFA concentration
The magnitude of decrease in plasma glucose concentration at day 1 did not significantly correlate with change in plasma insulin, glucagon or FFA concentration at day 1. However, it significantly and inversely correlated with plasma ketone concentration at day 1 (r = −0.63, P < .05) and increase in plasma ketone concentration from baseline to day 1, (r = −0.74, P = .01) (Figure 3 ). Plasma ketone concentration at day 1 strongly correlated with plasma FFA concentration at day 1 (r = 0.59, P < .05) and inversely correlated with plasma insulin concentration at day 1 (r = −0.51, P < .05). As anticipated, the decrease in plasma insulin concentration was associated with an increase in plasma FFA concentration (r = −0.55, P = .01).
The ketogenic index strongly correlated with plasma ketone concentration at day 1 (r = 0.85, P < .001) ( Figure 4 ) and day 14 (r = 0.64, P = .01) and a cut-off point of −0.9 predicted subjects in the upper tertile (with plasma ketone concentration > 0.6 mM, mean = 0.76 mM) with 86% sensitivity and 83% specificity.
| DISCUSSION
The present study reports several novel observations. Unlike in subjects with T2DM, emagliflozin did not affect FPG concentration in NGT subjects, despite marked glucosuria (50 g/d). Moreover, although glucosuria caused by empagliflozin in IFG subjects was comparable to that in NGT subjects, empagliflozin caused a small but significant decrease in FPG concentration in IFG subjects. Further, the magnitude of decrease in FPG concentration strongly and inversely correlated with FPG concentration in the entire cohort, and this relationship was maintained in non-diabetic individuals. The strong relationship between magnitude of decrease in FPG concentration and the FPG level in diabetic subjects can be explained by the fact that more glucose is removed from the body by SGLT2 inhibition as FPG concentration increases and more glucose is filtered in the glumerolus. 12 However, the differential effect of empagliflozin on FPG concentration between IFG and NGT subjects cannot be explained by differences in the amount of glucose removed by the kidney as this was comparable in both groups.
A previous study with dapagliflozin in NGT subjects has reported no effect of the drug on FPG concentration over 14 days of treatment. 13 These results suggest that it is likely that the decrease in FPG concentration in IFG subjects caused by empagliflozin is not simply explained by urinary glucose loss; rather, it is probably a correction of some of the underlying mechanisms responsible for the rise in FPG concentration in IFG subjects. 4 Relationship between the ketogenic index and plasma ketone concentration at day 1 after treatment with empagliflozin in NGT, IFG and T2DM patients. A novel Ketogenic Index based upon changes in plasma glucose, insulin and FFA can predict the increase in plasma ketone concentration after administration of an SGLT2 inhibitor. FIGURE 3 Relationship between change in plasma glucose concentration and change in plasma ketone concentration after treatment with dapagliflozin in NGT, IFG and T2DM patients.
